Literature DB >> 21722597

Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).

David C Klonoff1, Charles L Zimliki, Lcdr Alan Stevens, Patricia Beaston, Arleen Pinkos, Sally Y Choe, Guillermo Arreaza-Rubín, William Heetderks.   

Abstract

The Food and Drug Administration in collaboration with the National Institutes of Health presented a public workshop to facilitate medical device innovation in the development of the artificial pancreas (or autonomous system) for the treatment of diabetes mellitus on November 10, 2010 in Gaithersburg, Maryland. The purpose of the workshop was to discuss four aspects of artificial pancreas research and development, including: (1) the current state of device systems for autonomous systems for the treatment of diabetes mellitus; (2) challenges in developing this expert device system using existing technology; (3) clinical expectations for these systems; and (4) development plans for the transition of this device system toward an outpatient setting. The patients discussed how clinical science, system components, and regulatory policies will all need to harmonize in order to achieve the goal of seeing an AP product brought forward to the marketplace for patients to use.
© 2011 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722597      PMCID: PMC3192648          DOI: 10.1177/193229681100500336

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  17 in total

1.  Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.

Authors:  N Attia; T W Jones; J Holcombe; W V Tamborlane
Journal:  Diabetes Care       Date:  1998-05       Impact factor: 19.112

2.  Outcome measures for outpatient hypoglycemia prevention studies.

Authors:  Roy W Beck; Craig Kollman; Dongyuan Xing; Bruce A Buckingham; H Peter Chase
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

3.  The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.

Authors:  M J Castillo; A J Scheen; P J Lefèbvre
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

4.  Enhanced 911/global position system wizard: a telemedicine application for the prevention of severe hypoglycemia--monitor, alert, and locate.

Authors:  Eyal Dassau; Lois Jovanovic; Francis J Doyle; Howard C Zisser
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

5.  Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.

Authors:  A Scheen; M Castillo; B Jandrain; G Krzentowski; P Henrivaux; A S Luyckx; P J Lefèbvre
Journal:  Diabetes Care       Date:  1984 Jul-Aug       Impact factor: 19.112

6.  Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin.

Authors:  Eva Tsalikian; Craig Kollman; William B Tamborlane; Roy W Beck; Rosanna Fiallo-Scharer; Larry Fox; Kathleen F Janz; Katrina J Ruedy; Darrell Wilson; Dongyuan Xing; Stuart A Weinzimer
Journal:  Diabetes Care       Date:  2006-10       Impact factor: 19.112

7.  Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion.

Authors:  J C Pickup; G C Viberti; R W Bilous; H Keen; K G Alberti; P D Home; C Binder
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

8.  Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated patients with type 1 diabetes.

Authors:  M Orsini-Federici; J Akwe Akwi; V Canonico; R Celleno; P Ferolla; R Pippi; C Tassi; A Timi; M Massi Benedetti
Journal:  Diabetes Technol Ther       Date:  2006-02       Impact factor: 6.118

9.  Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.

Authors:  Stuart A Weinzimer; Garry M Steil; Karena L Swan; Jim Dziura; Natalie Kurtz; William V Tamborlane
Journal:  Diabetes Care       Date:  2008-02-05       Impact factor: 19.112

10.  Duration of nocturnal hypoglycemia before seizures.

Authors:  Bruce Buckingham; Darrell M Wilson; Todd Lecher; Ragnar Hanas; Kevin Kaiserman; Fergus Cameron
Journal:  Diabetes Care       Date:  2008-08-11       Impact factor: 19.112

View more
  4 in total

1.  Smart sensors for maintaining physiologic homeostasis.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

Review 2.  Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes.

Authors:  Ali Cinar
Journal:  Curr Diab Rep       Date:  2017-08-15       Impact factor: 4.810

3.  Design of the health monitoring system for the artificial pancreas: low glucose prediction module.

Authors:  Rebecca A Harvey; Eyal Dassau; Howard Zisser; Dale E Seborg; Lois Jovanovič; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

Review 4.  Wearable and implantable pancreas substitutes.

Authors:  Leonardo Ricotti; Tareq Assaf; Paolo Dario; Arianna Menciassi
Journal:  J Artif Organs       Date:  2012-09-20       Impact factor: 1.731

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.